Becton Dickinson and Co. (BDX) delivered a solid first quarter for fiscal 2026, but the real story is what happens next. The medical technology company reported adjusted earnings of $2.91 per share on Monday, comfortably beating the consensus estimate of $2.81. Revenue came in at $5.25 billion, slightly above expectations of $5.15 billion.
Here's the thing though: those numbers represent the old Becton Dickinson. The company is undergoing a major transformation, spinning off its Biosciences and Diagnostic Solutions business to merge with Waters Corporation (WAT). That deal was expected to close the same day as the earnings announcement, which explains why the company provided guidance for what it's calling "New BD."
And about that guidance—it's not pretty. Becton Dickinson slashed its fiscal 2026 adjusted earnings outlook from a range of $14.75-$15.05 per share down to $12.35-$12.65 per share. That's well below the consensus estimate of $14.72. The company's stock fell 3.77% to $202.10 in premarket trading, which makes sense when you're cutting profit forecasts by roughly 16% at the midpoint.
Overall revenues increased 1.6% as reported and 0.4% on an adjusted foreign exchange neutral basis. Not exactly explosive growth, but the underlying segments tell a more nuanced story.
Breaking Down the Segments
The Medical Essentials segment generated sales of $1.595 billion, up a modest 0.6% (down 0.6% on a foreign exchange neutral basis). Medication Delivery Solutions faced headwinds from order timing dynamics and volume-based procurement pressures in China, though these were partially offset by continued share gains in U.S. Vascular Access Management. Specimen Management brought in $468 million, dealing with similar challenges but seeing solid growth in the BD Vacutainer portfolio domestically.
Connected Care was a bright spot, generating $1.13 billion in sales, up 5.5% (4.7% on a foreign exchange neutral basis). Medication Management Solutions saw solid pharmacy automation growth driven by BD Rowa, while infusion performance strengthened thanks to order timing and higher infusion-set utilization. Advanced Patient Monitoring delivered strong volume growth across the portfolio, led by Smart Recovery, HemoSphere Alta Monitor, and continued adoption of the Acumen IQ Sensor.
BioPharma Systems posted sales of $429 million, up 2.7% (1% foreign exchange neutral). Double-digit growth in Biologics was partially offset by lower market demand for vaccine products—a reminder that the post-pandemic vaccine boom has definitively cooled.
The Interventional segment jumped 5.8% (5.1% foreign exchange neutral) to $1.33 billion. Peripheral Intervention sales of $485 million showed strength in peripheral vascular disease and oncology, despite volume-based procurement headwinds in China. Urology and Critical Care delivered $427 million with double-digit growth in the PureWick franchise as both Male and Female portfolios gained adoption. Surgery sales of $418 million reflected double-digit growth in Advanced Tissue Regeneration and high single-digit growth in Infection Prevention.
Then there's Life Sciences, which fell 8.3% (down 10.5% foreign exchange neutral) to $766 million. Of course, this is the segment being spun off, so these challenges won't be Becton Dickinson's problem much longer. Diagnostic Solutions generated $439 million, impacted by U.S. Point of Care headwinds, a difficult prior-year comparison, and market dynamics in China. Biosciences reported $327 million, hurt by China market dynamics, lower life sciences research funding, and a tough comparison with prior-year licensing revenue.
What Management Is Saying
"Today, we expect to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation. With this significant milestone in our strategy to drive shareholder value, we fully pivot to New BD and the next chapter of the company's growth—intensifying our focus on elevating commercial capabilities, advancing industry-leading innovation, and applying BD Excellence to drive productivity and gross margin expansion," said Tom Polen, chairman, CEO, and president.
Polen added that "our Q1 results have positioned us well to achieve our fiscal 2026 guidance while creating a foundation for long-term revenue and earnings growth."
That's the optimistic spin, but investors will need to see whether the slimmed-down company can actually deliver on the promise of improved margins and productivity now that it's shedding the struggling Life Sciences division.
How the Stock Stacks Up
Looking at Becton Dickinson's fundamentals compared to the broader market reveals some interesting dynamics. On the value front, the stock scores weak at 23.73, indicating it's trading at a steep premium relative to peers. That's a tough pill to swallow when you're simultaneously cutting earnings guidance. The quality score sits at a neutral 36.16, suggesting the balance sheet remains healthy despite the strategic reshuffling.
The verdict? It's a mixed picture. The healthy balance sheet is reassuring, but the premium valuation could be problematic for value-focused investors, especially with reduced earnings expectations. The company is making a big strategic bet that focusing on its core medical technology businesses will unlock value over time, but the market's initial reaction suggests some skepticism about the near-term outlook.
